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Introduction: Streptococcus pneumoniae is a major cause of morbidity and mortality in HIV-
positive individuals. Despite the widespread use of anti-retroviral medications, the incidence of 
pneumococcal disease is 20-40 fold higher in the HIV+ population compared to HIV- persons. 
Consequently, pneumococcal vaccination is recommended for all HIV+ individuals.  In 2012 the 
FDA changed vaccine recommendation from a single vaccination with the 23-valent 
pneumococcal polysaccharide vaccine (PPV23) to a dual vaccination with 13-valent protein 
conjugate vaccine (PCV13) followed by PPV23.  Studies demonstrating superiority of the 
PCV13/PPV23 regimen compared to PPV23 alone are limited and controversial.  The goal of this 
study was to analyze and compare the immune response to PCV13/PPV23 versus PPV23 in HIV-
positive individuals and age-matched HIV-negative persons.  
Methods: The participants for this study were recruited from the University of Toledo and 
MUSC.  We focused on aging HIV+ persons and all participants were 50-64 years of age. 
Participants were randomized to either PCV13 followed by PPV23 group or PPV23 only.  Blood 
samples were collected prior to vaccination and thirty days following the administration of 
PPV23 to analyze antibody responses and opsonophagocytic activity (OPA) to pneumococcal 
serotypes 3, 7 and 19A. Inflammatory markers were quantified by Luminex using serum 
samples on day 0. 
Results/Conclusions: OPA and pneumococcal-specific IgG antibody titers increased significantly 
from pre- to post-vaccination in all groups.  In HIV+ subjects, there was no significant difference 
in antibody or OPA responses to serotypes 3, 7F or 19A comparing PCV/PPV to PPV alone  In 
HIV-negative subjects, there was a significantly higher antibody response to serotype 19A only, 
but not to serotypes 3 and 7F in the group immunized with PCV13/PPV23.  However, no 
significant differences were observed in OPA between groups (which groups?).  Serum IP-10, 
TNF-alpha, IL-6, sCD40L, and APRIL were significantly higher in HIV+ compared to HIV-negative 
subjects.  There were no correlations between any of the tested inflammatory markers and 









Chapter 1: Introduction 
 
Hypotheses 
There is not a significant improvement in qualitative or quantitative antibody response after 
vaccination with both Prevnar-13 and Pneumovax-23 compared to those only receiving 
Pneumovax-23 alone in HIV+ and HIV- person 50-65 years of age 
 
There is a correlation between inflammation markers prior to vaccination and functional 
antibody response after vaccination. 
 
To test these hypotheses, the following groups were immunized with the following vaccination, 
and pre- and post-vaccination antibody and opsonophagocytic responses were analyzed: 
 
Group 1:  HIV- age 50-65 received PPV 
Group 2:  HIV+ age 50-65 received PPV 
Group 3:  HIV- age 50-65 received PCV followed by PPV 
Group 4:  HIV+ age 50-65 received PCV followed by PPV 
 
Specific Aim 1: Analyze the quantitative and qualitative antibody response as a surrogate 
measure of protection 
Rationale. Is there a difference in antibody response in groups receiving Prevnar-13 followed 
by Pneumovax-23 in comparison to those receiving only Pneumovax-23? 
Hypothesis 1. There is not a significant difference detectable in antibody and opsonophagocytic 
antibody response in HIV+ or HIV- individuals 50-65 of age immunized with PCV/PPV versus 
PPV. Methods: ELISA was used to analyze the titer of antibodies specific for three separate 
polysaccharides (3, 7F, and 19A), to determine if there is a difference between the two vaccine 









Opsonophagocytic assay was used to characterize the functional antibody response (3, 7F, and 
19A) in groups immunized with Pneumovax-23 vs. Prevnar-13 followed by Pneumovax-23.   
 
Specific Aim 2: Correlate the functional antibody response (or OPI) with markers of immune 
activation and inflammation. 
Rationale: Do markers of immune activation and inflammation correlate with OPI titers after 
vaccination? 
Hypothesis 2: The presence of inflammation as measured by inflammatory markers correlates 
with impaired vaccine response to neoantigens. 
Methods:  
Luminex Assay was used to analyze serum concentrations of: 
































Chapter 2: Review of the Literature 
 
Epidemiology 
 Streptococcus pneumoniae is a major cause of morbidity and mortality.  S. pneumoniae 
causes 500,000 cases of bacterial pneumonia and 50,000 cases of bacteremia per year. The 
organism is spread from person-to-person by direct contact through respiratory secretions, 
such as saliva or mucus.  The primary reservoir for S. pneumoniae is in the nasopharynx (Simell 
B, 2012).   Colonization of either the nasopharynx or oropharynx is often the initial step in 
pathogenesis (Rabquer B, 2007).   Asymptomatic colonization with the bacteria is known as 
carriage.  It has been shown that when symptomatic infections do accompany colonization, 
they typically occur within a few weeks after acquiring a new strain (Bennett J, 2012).  
Moreover, chronic carriage results in the production of antibody, protecting against invasive 
disease (Murphy, 2014). 
 The pneumococcus can cause a range of diseases from bronchitis to sepsis, however, 
the most common presentations are otitis media, bacteremia, meningitis, and pneumonia. 
Otitis media (inner ear infection) is most common in young children, with about seven million 
cases each year (ACIP, 2000).  The ability of this pathogen to disseminate from infections 
localized to the middle ear and the lungs to more invasive disease, is one feature that makes 
this pathogen so dangerous.  S. pneumoniae is the number one cause of bacterial pneumonia.  
It has been estimated that more than a million children under the age of five die from 
pneumococcal pneumonia each year.   Almost five in 1000 persons contract pneumococcal 
pneumonia yearly, with higher rate in the very young and the elderly (Ortqvist A, 2005).   
   
The pathogen and virulence 
Pneumococcal serotypes can be differentiated based on the outer polysaccharide 
capsule.  This capsule is the bacteria’s primary defense against phagocytosis and subsequent 
clearance (Ortqvist A, 2005).  The polysaccharide capsule that surrounds the bacteria allows S. 









ninety different serotypes of pneumococcus, only a few serotypes cause the majority of 
pneumococcal infections.  It is estimated that 62% of invasive pneumococcal disease (IPD) 
worldwide can be attributed to ten common serotypes of S. pneumoniae (CDC, Pneumococcal 
Disease, 2015).  
The polysaccharide capsule may be the most well-known virulence factor of the 
bacteria.  Host-mediated killing of S. pneumoniae results from antibodies directed against the 
polysaccharide capsule (Gillespie S, 2000).  This happens through deposition of serotype 
specific antibodies on the bacterial surface to act in combination with complement proteins 
leading to opsonization and clearance.  Despite the structural diversity all but two of the 
serotypes of pneumococcus are synthesized by the Wzy-dependent mechanism (Yother, 2011).  
Serotype 3 and 37 use their own distinct mechanism for polysaccharide synthesis (Choi E, 
2016).  The different mechanism of capsular polysaccharide synthesis may explain why these 
serotypes have a thicker capsular polysaccharide compared to the other serotypes, which could 
attribute to poor immunogenicity.   
 The antibody response to S. pneumoniae is serotype-specific based on the capsular 
polysaccharide (Henrichsen, 1995).  Serotype-specific immunity means that the antibody 
response is made to each pneumococcal serotype independently after exposure of a new 
serotype.  In certain circumstances, however, the polysaccharide sequence is similar and can 
offer cross reactive protection (CDC, Pneumococcal Disease, 2015).  This is the case between 
serotypes 19F and 19A as well as others.  
 The polysaccharide capsule is considered the primary virulence factor of S. pneumoniae, 
as non-encapsulated strains are less virulent.  While this is true, there are many other virulence 
factors that contribute to the disease process including; hyaluronate lyase, pneumolysin (Ply), 
two neuraminidases, autolysin, choline binding protein, pneumococcal surface antigen A, and 
pneumococcal surface protein A (PspA) (Jedrzejas, 2001).  These virulence factors have the 
potential to act as future targets for vaccination either alone or in conjugation with current 









targets.  PspA, located on the cell wall of pneumococci, functions to inhibit opsonization and 
phagocytosis of pneumococci by the host’s complement system (Jedrzejas, 2001).  PspA evades 
complement clearance by reducing the amount of C3b deposition of pneumococci (Anh-Hue T, 
1999).  PspA is immunogenic in mice, eliciting antibodies that can protect them from 
pneumococcal strains expressing the protein (McDaniel L, 1987).  Another study using nasal 
colonization of S. pneumoniae in mice showed that Ply is important in initial nasopharyngeal 
establishment and colonization.  Ply functions to disrupt epithelial junctions and creates pores 
in cholesterol containing membranes, causing host cell lysis leading to severe tissue damage 
and inflammation (Molloy, 2011) (Hotorni M, 2016). Thus, Ply and PspA are also major virulence 
factors that contribute to S. pneumoniae evading the immune system and causing invasive 
infection.  
 
Immunity and capsule 
Polysaccharides are composed of a repeating epitopes of long monosaccharide 
molecules bound by glyosidic linkages.  The repetitive structure of the epitopes classifies them 
as a T cell independent type 2 antigen (TI-2).  T cell independent antigens can stimulate 
humoral antibody response from the B cells independent of T cell interaction or presence 
(Mond JJ V. Q., 1995).  TI-2 antigens, due to their highly repetitive nature, are capable of 
crosslinking the B cell receptors (BCR) (Mond JJ L. A., 1995).  Crosslinking the BCR causes them 
to cluster on the cell surface initiating a signaling cascade that is able to induce gene 
transcription, translation and cause subsequent B cell proliferation, differentiation, and 
antibody production (Mond JJ L. A., 1995).  The secreted anti-polysaccharide antibodies bind to 
their complementary antigens on the surface of the bacteria marking them for phagocytosis 
and clearance (Murphy, 2014).  This mechanism, however, can only activate mature B 
lymphocytes and produce IgM antibodies (This is interesting, any mechanism for only IgM?).  
Immature B cells are not able to respond to polysaccharide.  In fact, interactions 









response (Mond JJ L. A., 1995) (Vos Q, 2000).  The mechanism of TI-2 antigen interacting with 
BCR through crosslinking is not known to produce cytokines (what cytokines?) that would allow 
for antibody class-switching (Mond JJ V. Q., 1995) (Mond JJ L. A., 1995).  It is postulated, 
however, that through the presence of other immune cells (i.e. macrophages, natural killer 
cells, and dendritic cells) there may be interactions that would allow for secretion of necessary 
cytokines to induce IgG production (Mond JJ L. A., 1995) (Mond JJ V. Q., 1995). 
 
Vaccines 
 In an effort to prevent invasive pneumococcal disease, two vaccines are currently 
approved by the FDA.  As mentioned previously the immune response to pneumococcus is 
serotype specific and a vast majority of the pneumococcal polysaccharides are not cross-
reactive.  In order to effectively offer some protection from pneumococcus a vaccine would 
need to cover a number of serotypes to protect against IPD.  
  Pneumovax-23 (PPV) is the 23 valent polysaccharide vaccine that is currently marketed 
for those over the age of 50 or those that have a compromised immune system.  This vaccine 
contains the capsular polysaccharide of 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 
17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F (see table 2 for vaccine comparison.  PPV contains 
capsular polysaccharide to induce serotype-specific antibodies that enhance opsonization and 
phagocytosis to offer protection from S. pneumoniae.  PPV uses the TI-2 antigen mechanism to 
activate the B cells and produce an immune response to the polysaccharide.  The immune 
response to PPV consists of mainly IgM antibodies, however, it is postulated that cytokines 
secreted from dendritic cells and macrophages can lead to class switching to IgG (Aaberge I., 
1992).   
 Eighty percent of healthy adults respond well to this vaccine and within 2-3 weeks 
develop antibodies against the included serotypes.  Pneumovax has been shown to provide 50 
to 80% protection in adults against invasive pneumococcal infection (Musher, 2013).  This 









thus in certain cases, revaccination is recommended after five years of the initial vaccine.  
Severe (arthus-type) reactions are more frequent when vaccination occurs less than five years 
apart (Artz A, 2003).   
PPV has an 82% effectiveness at preventing bacteremia in healthy adults.  However, in 
the population over the age of 65, the efficacy of preventing bacteremia decreases to 44% 
(CDC, 2015).  While PPV has been known to be beneficial in preventing IPD, there is no clear 
evidence that there is a benefit in reducing the incidence of community acquired pneumonia 
(CDC, 2015) (Jackson L, 2008).   In patients at a high risk for IPD, it has been shown that the 
antibodies produced in response to PPV are only a 30% specific for the polysaccharide antigens 
included in the vaccine.  Moreover, 70% of antibodies are non-specific and non-functional (Huo, 
2002). 
 The first generation glyco-conjugate vaccine, PCV-7, proved to be highly beneficial at 
preventing IPD in children.  PCV-7 uses diphtheria toxin, CRIM-197 conjugated to 
polysaccharide, to induce an immune response that utilizes T cell help (Dagan R, 2010).  
Widespread use of PCV-7 resulted in virtual eradication of the vaccine serotypes, however, 
serotypes including 3, 7F, and 19A replaced previous circulating strains and are now a leading 
cause of IPD (Richter, 2013) (ACIP, 2000).  Glyco-conjugated vaccines were originally developed 
to overcome the poor immunogenicity of the capsular polysaccharide in children <2 years of 
age (Goldblatt, 2000).  Young children are able to respond to conjugated polysaccharide 
vaccines because it is not dependent on mature B cells (Shields, 2001).The conjugate 
polysaccharide vaccine, allows the BCR to recognize the immunogenic protein conjugated to 
the bacterial polysaccharide.  The polysaccharide and carrier protein is internalized, degraded 
(processed), and presented by the polysaccharide-specific B cell in context of MHC II, to carrier 
protein specific T cells.  As shown in 2011, there are specific T cell populations that recognize 
carbohydrate epitopes derived by APC processing of the conjugate vaccines and that, when 
presented by MHCII, these epitopes recruit T cell help for the induction of adaptive immune 









cell receptor induces the B cell to differentiate into polysaccharide specific memory B cells and 
plasma cells to produce anti-polysaccharide antibodies (Parham, 2014).  Conjugate vaccines, by 
virtue of inducing a T cell dependent immune activation allows for production of 
polysaccharide-specific memory B cells and polysaccharide-specific plasma cells creating a 
longer lived immune response (Feldman C, 2014).  
Following widespread vaccination of children with PCV-7, the rates of otitis media and 
bacterial pneumonia decreased.  A 93% decrease in rates of childhood IPD marked the 
vaccination strategy’s success.  The serotypes included in the first generation of PCV (PCV-7 
which included seven serotypes) were reduced from circulation by 97% (Black S, 2002).  PCV-7 
thus, provided protection in adults regardless of vaccination status (Eskola J, 2001).  PCV-7 does 
have drawbacks which include limited serotype coverage and a difficult manufacturing process 
resulting in an increased expense compared to PPV.  PCV-7’s limited serotype coverage allowed 
for serotype replacement by other pneumococcal strains that are not covered in the vaccine 
(Gruber W, 2012). Thus Prevnar-13 (PCV) was created as the second generation glycol-
conjugated polysaccharide vaccine.  This thirteen valent vaccine includes the capsular 
polysaccharides from of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F (Darkes 
M, 2002)(see table 2 for vaccine serotype comparisons).   
 
High risk populations 
Invasive pneumococcal disease has been shown to primarily affect; young children, the 
elderly, and the immunocompromised populations.  Despite the recent advances in vaccination 
procedures against pneumococcus for these at risk groups, the incidence of IPD remains high.  
Young children are unable to respond to the polysaccharide as they have not had ample time to 
for their B cell repertoire to recognize polysaccharides.    
In contrast elderly populations have immune deficiencies associated with age, excessive 
inflammation, or other underlying comorbidities.  A reduction in isotype-switching and somatic 









produced in response to polysaccharide (Hart M, 2007).  These mutations can change the way 
the antibody binds to its respective antigen and decrease the antibody’s functionality to induce 
a phagocytic response (Khaskhely N, 2012). 
It has also been shown that those individuals with a low number of circulating IgM 
memory B cells, such as the elderly and immunocompromised individuals, responded poorly to 
the polysaccharide vaccines.  In the elderly population and HIV-infected individuals both the 
absolute and relative numbers of IgM memory B cells are decreased compared to young adults 
(Leggat D, 2013).  IgM memory B cells are able to respond immediately following recognition of 
a TI antigen such as polysaccharide, and without these cells, these populations are more 
susceptible to pneumococcal infections (Khaskhely N, 2012) (Rabquer B, 2007).  
It has been reported that the elderly and HIV+ adults secrete normal levels of IgG 
antibodies in response to pneumococcal capsular polysaccharide.  However, both the elderly 
and the HIV-infected population have lower levels of IgM antibodies compared to younger 
adults (Madhi S, 2005) (Park S, 2011).  The elderly population also show poor functional or 
opsonophagocytic antibody activity.  Complement mediated killing of pneumococci is more 
efficient with anti-polysaccharide IgM antibodies compared to IgG antibodies.  Secreted IgM is 
more likely to present in a heptamer conformation, clustering the immunoglobulins’ constant 
region.  This conformation gives C1 (the first complement protein in the cascade) an increased 
ability to bind to IgM compared to IgG, which would need several constant regions clustered 
together to achieve the same effect (Sarma J, 2011).  Furthermore, it has been stated that a 
deficiency in concentrations of IgM alone may explain the functional differences between 
young and old adults or HIV+ patients immunized with only PPV in reference to some serotypes 
(Park S, 2011).   
The process of aging can be characterized by a chronic and low grade inflammation.  
This process has termed as “inflammaging”, which describes a low-grade, chronic, systemic 
inflammation that occurs in the aging population, in the absence of an infection or immune 









morbidity and mortality in the elderly population.  Elevated inflammatory biomarkers such as 
TNF- alpha, C-reactive protein, and IL-6 are predictive of many aging phenotypes including 
metabolic homeostasis, body composition, immune senescence, and neuronal health (Woods J, 
2012).   Inflammation can be beneficial in an acute immune response to a traumatic injury or an 
invading pathogen.  However, when this response becomes misguided and chronic, it can 
impair a beneficial inflammatory response and lead to increased susceptibility to infections.  
Chronic inflammation is generally thought to cause tissue degradation, however, it can 
also lead to the normal process of tissue remodeling.  Centenarians often have signs of systemic 
inflammation, marked by higher plasma levels of IL-6 and IL-8 (Minciullo P, 2016) (C Franceschi, 
2007).   These individuals avoid or delay the onset of many chronic age-related diseases such as 
cardiovascular disease, invasive cancer, and type II diabetes despite the presence of high levels 
of inflammatory markers (C Franceschi, 2007).  It’s possible that in some cases systemic 
inflammation can be adaptive rather than always being pathogenic. 
 While in certain cases inflammation may be adaptive, there is evidence that 
inflammaging may affect both adaptive and humoral immune responses (Frasca D. B. B., 2016).  
B cells express innate immune receptors that can recognize pathogens or adjuvants to induce 
an immune response to them (Frasca D, 2009).  B cells can either act as antigen-presenting cells 
to promote the immune response or secrete inhibitory cytokines to regulate and suppress the 
immune response (Frasca D, 2009).  Previously it has been shown that incubation of B cells with 
TNF-alpha decreased the ability of B cells to respond to LPS (Frasca D. R. M.-W., 2012).   
Increased expression of TNF-alpha and other inflammatory markers prior to vaccination may 
decrease the ability for B cells to respond and efficiently produce antibodies.   
 
Combined effects of Aging and HIV-infection 
 Individuals that are HIV+ have a 40 to 50 fold higher risk of developing IPD compared to 
age matched HIV- populations.  Those that are HIV+ and over the age of 50 are thought to have 









widespread use of antiretroviral therapy (ART) (Levy-Dweck, 2005).  ART is a combination of 
several antiretroviral drugs that are used to lessen or halt the rate at which HIV replicates in the 
body.  The use of combination therapy is beneficial because they block HIV replication at 
different points in the cycle.  Viral suppression results in increased number of circulating T cells.  
HIV preferentially replicates within T cells, which in turn induces apoptosis through the 
initiation of the caspase cascade, thereby eliminating T lymphocytes (Jaworowski A, 1999) 
(Fevrier M, 2011) (Douek D, 2002).  It has been estimated that at least 3.0 million years of life 
have been saved in the US as a direct result of the advances in HIV disease treatment (Walensky 
RP, 2006).   Presently over half of the HIV-positive population in the US are over the age of 50 
(Walensky RP, 2006). 
The process of aging in combination with the extended exposure to HIV infection and 
ART appears to increase the risk of illness and death from HIV-associated non-AIDS conditions 
such as; cardiovascular, kidney, bone, liver, and lung disease as well as many cancers not 
directly associated with HIV infection (Guaraldi G, 2011).   In addition, it was found that HIV 
positive individuals were more likely to develop to other comorbid illnesses as they age 
compared to their HIV-negative counterparts (Goulet JL, 2007).  HIV infection alone causes 
chronic inflammation, which increases risk of other conditions like heart disease and other 
cancers.  
 HIV+ infection can directly affect the B cell population leading to increased apoptosis, 
increased production of inflammatory cytokines, hyper-activation, and decreased class 
switching.  Hyper-activation of B cells caused by HIV is characterized by; 
hypergammaglobulinemia, increased polyclonal B-cell activation, increased cell turnover, 
increased activation marker expression, increased differentiation into plasma-blasts, increased 
production of autoantibodies, and an increase in the frequency of B-cell malignancies (Fauci, 
2009).  Ongoing HIV replication and persistent infection also have the ability to induce B cell 
exhaustion (S Moir, 2008)  Although most B-cell defects caused by HIV infection can be 









memory B cells (Fauci, 2009) (S Moir, 2008).  Similarly, aging also decreases humoral responses.  
Individuals over the age of 65 show lower numbers of overall B cells and a decreased number of 
memory B cells (Frasca D, 2009).  Overall, aging and HIV infection both show a decrease in the 
total number of B cells and in the number of memory B cells. HIV infection has been previously 
described as an accelerated aging immune environment deemed as immune-aging (Deeks, 
2011).  Therefore, it can be postulated that the aging HIV infected population is expected to 
have an increased inflammatory environment that could lead to increased susceptibility for 
many opportunistic infections including pneumococcal pneumonia.  Thus aging HIV+ individuals 
have two separate risk factors predisposing them to IPD, namely aging and HIV infection 
  
Vaccine recommendations 
 Prior to 2012, Pneumovax-23 was recommended for all individuals over the age of 65 
and those with a compromised immune system.  The recommendation was changed in 2012 to 
include vaccination with the newly marketed “adult” conjugate vaccine, PCV-13, potentially 
enhancing the immune response (ACIP, 2000).  
 Prevnar-13 uses the interaction with carrier-protein specific T cells to induce 
differentiation of B cells to secrete polysaccharide specific antibodies.  HIV infection is generally 
characterized by a low or dysfunctional T cell pool.  Could vaccination with PCV 8 weeks prior to 
PPV be beneficial in protecting the aging HIV+ population from pneumococcal infection?  
Previously published work suggests that the recommended PCV/PPV regimen may not 
significantly improve quantitative or functional antibody responses to pneumococcal 
polysaccharide 14 or 23F when compared to PPV only, in aging HIV+ subjects (Ohtola J, 2016).  
These studies, however, did not examine the antibody responses to other pneumococcal 
polysaccharide 3, 7F, or 19A.  As these results showed distinct difference in the immune 
response to PPS 14 and PPS 23F, we thought it necessary to expand the scope of our study to 










Pneumococcal polysaccharide 3 has one of the thickest polysaccharide capsules.  The 
thick envelope surrounding the bacterium is shown to be protective against complement-
mediated clearance.  The thick capsular polysaccharide serotype 3 synthesizes its capsular 
polysaccharide by the synthase-dependent pathway, resulting in a polysaccharide that is not 
covalently linked to peptidoglycan, meaning it has the ability to be released during growth (Choi 
E, 2016).  The efficacy of PCV-13 at preventing pneumococcal infection against serotype 3 still 
remains unclear, however, it has been shown that released capsular polysaccharide from 
serotype 3 interferes with antibody-mediated killing and protection by anti-capsular 
polysaccharide antibodies (Choi E, 2016).  Thus, receiving both PCV followed by PPV compared 
to receiving PPV alone may be beneficial in aiding protection from serotype 3.  Serotype 3 
isolates were found more frequently in adults and children over the age of five rather than 
young children (Imohl M, 2010). Thus, as age increases the risk of pneumococcal infection 
caused by serotype 3 is also increased (Imohl M, 2010).  
Following the implementation of PCV-7 in children two serotypes that emerged as being 
prominent causes of IPD in children included pneumococcal polysaccharides 7F and 19A 
(Chacon-Cruz E, 2012).   These two serotypes were associated with about 30% of cases of 
pneumococcal pneumonia (Kaplan, 2010). 
Serotype 7F isolates were the most common isolates causing otitis media but even more 
importantly, were more commonly recovered from invasive than noninvasive specimens 
(Shields, 2001).  Another study in Germany of invasive pneumococcal disease in children over 
sixteen, revealed the highest risk for severe and fatal outcomes for infection were with 
serotype 7F (Imohl M, 2010).  Pneumococcal serotype 7F was reported to isolated more in 
children under four months of age than the individuals among the other age groups (Shields, 
2001). 
 Similarly, following the introduction of PCV-7, colonization and disease associated with 
serotype 19A increased (Kaplan, 2010).  By 2005, serotype 19A had emerged as the most 









proportion of resistant invasive infections (Moore MR1, 2008).  Serotype 19A was shown to 
have a greater ability to cause invasive disease than other non-PCV7 isolates that emerged, 
however, the exact cause is not known.  In addition, serotype 19A, showed decreased 
susceptibility to the most commonly used antibiotics including; penicillin, ceftriaxone, 
azithromycin, and trimethoprim-sulfamethoxazole (CDC, 2008).  Thus, 19A emerged as one of 
the main antibiotic resistant pneumococcal strains in circulation.  
 Pneumococcal polysaccharide 3, 7F, and 19A are included in PCV-13 and PPV-23.  These 
strains are shown to be a cause for concern due to their poorly immunogenic nature, increased 
incidence of infection, and antibiotic resistance, especially in a population with increased 


























Chapter 3: Methods 
Study population and design  
 Thirty-eight HIV-positive patients between the ages of 50 and 64, who had not received 
pneumococcal polysaccharide vaccines within the last five years were recruited from the 
University of Toledo Medical Center between 2012 and 2014.  Two additional HIV- positive 
patients were recruited from the Medical University of South Carolina Infectious disease clinic 
in 2016.  All of these HIV-positive patients had a CD4 count above 200 and nadir CD4 count 
greater than 200.  The twenty-five HIV negative patients were recruited from the University of 
Toledo Medical Center between 2014 and 2015 while the patients recruited in 2016, were 
recruited at the Medical University of South Carolina. (IRB# Pro00046749).  
All volunteers were screened for exclusionary conditions including: cancer, autoimmune 
diseases, end stage renal or liver disease, organ transplantation, splenectomy, 
immunosuppressive medication, pregnancy, bleeding disorders, and previous pneumococcal 
vaccination within the last five years (through a review of their medical records and in-person 
screening prior to collecting consent).  Informed consent was obtained from all participants 
prior to enrolling into the study.  Volunteer baseline information was obtained from all 
participants including: age, gender, ethnicity, treatment with ART, patient history, hepatitis 
status, list of current medications, and blood tests (complete blood count with differential, 
basic metabolic panel, liver function tests, HIV viral load, and T cell subset analysis).   
 HIV-positive individuals were randomized to one of two separate vaccination groups; 
the dual vaccination groups in which the participants receive PCV-13 on the day zero and at 
least eight weeks later were vaccinated with PPV-23, while the single vaccination group only 
received PPV-23 on day zero.  The HIV+ PCV/PPV had nineteen participants (referred to as 
group 4) whereas the PPV HIV+ group had twenty-one participants (group 2).  The HIV- 
participants were divided into dual vaccination and single vaccination groups, ten volunteers in 









All adverse reactions to vaccination were recorded.  Five volunteers experienced 
redness and slight soreness following vaccination.  All work was conducted in adherence of the 
Declaration of Helsinki.  All volunteers who enrolled, successfully completed the study.   
 
Collection of Samples 
 Blood samples were collected at day 0 and day 30 for PPV 23 only, and day 0 and day 90 
for the PCV13/PPV23 groups. These blood samples were subjected to ELISA and 
opsonophagocytic assay.  Luminex analysis of ten key inflammatory markers was performed 
using pre-immunization sera.   
 
Total PPS-specific antibody titers:   
ELISAs were performed using day zero and thirty days’ post PPV and day 0 and day 90 
post PCV/PPV immunization serum samples along with serum standard 007sp (post-vaccination 
pneumococcal standard).  Both control and volunteer serum samples were absorbed with 22F 
and cell wall polysaccharide (CWPS) based on the World Health Organization (WHO) published 
ELISA training manual (Organization, 2016).  Briefly Nunc Maxisorp 96 well plates were coated 
with 15g/ml PPS 3, 7F, or 19A and incubated overnight at 37C.  Absorbed plates were washed 
with wash buffer (1XPBS/ 0.05% Tween-20).  After blocking the plates (1X PBS/ 1% BSA buffer), 
serially diluted absorbed sera were added to the plates and incubated at 37C.  Plates were 
washed, and bound antibody was detected using HRP-conjugated anti-human IgG (Southern 
Biotech).  Plates were developed using o-phenylenediamine substrate and read at 490 nm on a 
microplate reader.  Linear regression fits were used to determine the antibody concentrations 
and were reported as g/ml (Wernette CM, 2003) (Skovsted IC, 2007).    
 
Functional PPS-specific antibody titers:   
Opsonophagocytic assay was performed using day 0 and day 30 post-PPV and day 0 and 









JY, 2013).  Briefly, serotype 3, 7F, and 19A were incubated with serially diluted heat-inactivated 
donor sera.  Newborn rabbit serum (Pel-Freez, Brown Deer, WI) was added as a source of 
complement.  Differentiated HL-60 cells were added at an E:T ratio of 400:1.  The 
opsonophagocytic titer was defined as the reciprocal of the dilution with 50% killing when 
compared with serum free controls and analyzed using the Opsotiter1 software developed by 
the University of Alabama at Birmingham (Song JY, 2013).  
 
Inflammatory marker analysis:   
To analyze inflammatory markers, we utilized a Luminex assay.  A Luminex is an 
immunoassay that enables us to simultaneously (in one test) detect and quantify multiple 
secreted proteins that are found in our volunteer sera.  This is similar to analysis by ELISA 
except that these analyses provide us with greater efficiency, speed and dynamic range.  
Luminex analysis for the following inflammatory markers was performed by EveTechnologies 
(Calgary, Alberta, Canada); BAFF, APRIL, IL-10, Il-1Ra, IL-8, Il-6, sCD40L, IP-10, IL-1B, and TNF-
alpha, using pre-vaccination sera.  
 
Statistical analysis  
 Pre and post-vaccination values within a single group was analyzed using a two-tailed 
paired t-test.  Comparison of groups with different vaccination strategies was performed using 
analysis of variance (ANOVA) with Tukey post-hoc test. Data is presented as mean +/- standard 
error of the mean (SEM).  Correlations between post-vaccination OPA titers and inflammatory 
markers were examined using a Spearman Correlation test.  P-values <0.05 were considered 













Chapter 4: Results 
Study Population 
 There was no difference in age of participants between the four groups.  The HIV-
infected groups were not different between current CD4, nadir CD4, and viral load between 
vaccination groups (table 1). 
 
ELISA 
 We found a significant increase in anti-polysaccharide IgG antibody concentrations from 
pre- to post-immunization in response to pneumococcal serotype 3, 7F, and 19A in all groups 
except for the HIV-infected group immunized with PPV alone in response to PPS 3 (figure 1-4 
panel A).   
Examination of polysaccharide specific IgG against pneumococcal serotype 3 and 7F 
revealed that there was not a significant difference between dual and single vaccination in 
either HIV-infected or HIV-uninfected groups (figures 3-4 panel a and b respectively).  In 
contrast, the IgG response to 19A was significantly higher in PCV/PPV immunized HIV-infected 
and HIV-uninfected groups versus PPV immunized groups (figures 3-4 panel C). 
 Anti-polysaccharide 3 and 7F IgG concentrations did not differ significantly between 
HIV- or HIV+ between either the PPV groups or the PCV/PPV groups after vaccination (figures 1 
and 2 panels A and B respectively).  However, anti-polysaccharide 19A antibody concentrations 
were significantly higher in the HIV- group compared to HIV+ in the PCV/PPV immunized 
groups, but not in the groups vaccinated with PPV alone (figure 1 and 2 panel c).  
 
Opsonophagocytic assay  
 Opsonophagocytic assays demonstrated that there was a significant increase in 
polysaccharide 3 specific antibody-mediated killing pre- to post-vaccination in all groups 
(figures 5-8 panel A).  In response to PPS 7F there was a significant increase in bacterial killing 









vaccinated with either PCV/PPV or PPV alone (figures 5-8 panel B).  Bacterial killing specific to 
PPS-19A showed a significant increase pre- to post-vaccination for HIV- infected and HIV-
uninfected groups immunized with PCV/PPV, however, there was no increase in either group 
vaccinated with PPV alone (figures 5-8 panel C).   
 The HIV-uninfected group vaccinated with PPV alone revealed a significant increase in 
serotype 3 and 7F specific bacterial killing compared to HIV-infected group (figure 5a-b).  There 
was no difference after vaccination in serotype 3 and 7F specific bacterial killing ability between 
HIV- and HIV+ groups vaccinated with PCV/PPV (figure 6a-b).  Opsonophagocytic bacterial 
killing for pneumococcal serotype 19A showed no significant differences between HIV- and 
HIV+ for either treatment groups (figures 5c and 6c respectively). 
There was no significant difference in functional antibody responses between PCV/PPV 
and PPV to any of the polysaccharides or groups tested (figure 5 and 6).    
 
Correlation between anti-PPS ELISA and OPA 
 There was no direct correlation between anti-PPS specific antibody concentrations and 
opsonophagocytic responses after vaccination (data not shown).   
 
Luminex  
 Ten markers of immune activation were tested by Luminex assay using pre-
immunization sera (figure 9 a-j).  These studies demonstrated that of the ten immune activation 
markers tested serum levels of APRIL (P=0.0002), sCD40L (P=0.0187), IL-6 (P=0.0239), TNF-alpha 
(P=0.0001), and IL-10 (P=0.0343) were significantly higher in HIV-infected compared to HIV-
uninfected persons.   
 
Correlation of Luminex and OPA 
  We correlated post-immunization OPA responses with baseline (day zero) inflammatory 









specific opsonophagocytic titers and TNF-alpha concentrations in the HIV-uninfected group 
vaccinated with PPV only (r=0.7112, P=0.0211) (figure 11e).  Group 3 (HIV-infected group 
vaccinated with PCV/PPV) had three instances in which there was a negative correlation with 
serotype 3 OPA titers and inflammatory markers sCD40L (r=-0.556, p=0.016), IL-8 (r=-0.51, 
p=0.038), and IP-10 (r=-0.55, p=0.018) (figures 11d, h, and j).  There was no other positive or 
negative correlation between serotype 3 specific opsonophagocytic killing and any of the other 
inflammatory markers tested including IL-6 (figures 10-13).   
 The opsonophagocytic antibody activity against serotype 7F pneumococci correlated 
well with IL-8 levels in the HIV+ group (r=0.495, P=0.031) vaccinated with PPV only (figure 14h).  
In group 4 (HIB-infected adults vaccinated with PCV-13 followed by PPV there was two 
instances of negative correlation with bacterial killing for 7F and inflammatory markers BAFF 
(r=-0.436, p=0.048) and IL-6 (r=-0.525, p=0.014) (figure 16 b and g). There was no other positive 
correlation present for any of the inflammatory markers with antibody mediated post 
vaccination killing versus serotype 7F in either HIV-infected or HIV-uninfected groups 
immunized with either regimen (figured 14-17).  
 Analysis of antibody mediated killing specific to 19A demonstrated a positive correlation 
with sCD40L (r=0.816, P=0.006) in the HIV- group vaccinated with PPV (figure 19d), however, 
this was not seen for the other vaccination group or any of the HIV+ groups.  In group 1 there 
was a negative correlation seen with OPA titers to 19A and IL-10 (r=-0.485, p=0.026) (figure 
18c).  There was no other positive correlation present for any of the other inflammatory 
markers and post vaccination killing ability for 19A with the other groups for either treatment 
group (figured 18-21).   
 Notably, we found no correlation between the five inflammatory markers that were 












Chapter 5: Discussion 
 The current study is the first, to our knowledge, to assess the pneumococcal serotype 3, 
7F, and 19A humoral immune response to pneumococcal vaccination in older HIV-infected 
individuals.  Our findings suggest that the PCV/PPV vaccination regimen may not offer superior 
protection from S. pneumoniae compared to vaccination with PPV alone in this population.  
Vaccination of HIV-infected individuals with either PPV or PCV/PPV resulted in significant but 
similar increases in serotype-specific IgG levels compared to baseline levels.  However, post-
vaccination OPA titers in the older HIV+ population were increased in response to serotype 3 
(both PPV and PCV/PPV) and 7F (PCV/PPV) but not in response to serotype 19A regardless of 
vaccine regimen.  However, titers in response to serotype 19A started higher than the post-
vaccination titers for serotypes 3 and 7F.  
 Extensive defects in humoral immunity is a result of HIV disease progression.  Impaired 
antibody responses to pneumococcal vaccination is associated with B cell functions, that are 
incompletely restored by ART (Hart M, 2007) (Titanji K1, 2006).  Previously we have shown that 
both HIV+ adults untreated and those treated with ART, exhibit reduced serotype-specific IgM 
memory B cells after PPV vaccination compared to HIV- individuals (Leggat D, 2013) (Iyer A, 
2015).  These results suggest that despite higher CD4 counts and use of ART, persistent cellular 
defects are likely to cause decreased antibody responses in our HIV+ patients post vaccination 
with either PPV or PCV/PPV.   
 Our results, demonstrating that vaccination with PPV and PCV/PPV elicit similar 
responses is consistent with some (Ho YL, 2013) (Peñaranda M, 2010) but not all (Feikina D., 
2001) (Lesprit P & Group., 2007) (Sadlier C., 2016), previous studies in HIV+ individuals.  
 The two studies that were consistent with our results in HIV-infected adults vaccinated 
with PCV/PPV compared to PPV.  These studies analyzed their post-vaccination responses thirty 
days after vaccination with PPV by comparing both functional and quantitative antibody 
response (Ho YL, 2013) (Peñaranda M, 2010).    However, in the studies by Peñarando et al. the 









(Peñaranda M, 2010).  Unfortunately, both studies were conducted using the PCV-7 which does 
not include serotypes 3, 7F, or 19A, therefore direct comparison with our study is not possible.  
These studies were also conducted over a wide range of ages with the median age around 44 
whereas, our study focuses on the aging HIV-infected population (Ho YL, 2013) (Peñaranda M, 
2010).  This is a crucial difference as the response to pneumococcal vaccination is age-
dependent. 
 A study published in 2001 tested the differences in immunity after pneumococcal 
vaccination comparing PCV-7 followed by PPV compared to a single vaccination of PPV (Feikina 
D., 2001).  The focus of this study was to compare the antibody responses through IgG ELISA 
and OPA titers to pneumococcal serotypes 4, 6B, 9V, 14, and 23F in HIV-infected adults (Feikina 
D., 2001).  This study did find increased OPA titers and antibody concentrations for those 
vaccinated with PCV followed by PPV compared to PPV alone.    
  The second study, conducted in France, compared the antibody responses to 
Pneumococcal serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F (the seven serotypes contained in 
PCV-7) (Lesprit P & Group., 2007).  This group analyzed the antibody response using end points 
of four-weeks and six months after vaccination with PPV, contrasting from our study which only 
used the end point of four-weeks after PPV vaccination (Lesprit P & Group., 2007).  In our study 
we analyzed antibody responses at thirty days after vaccination because this is the peak time 
point to capture the circulating antibody response to polysaccharide.  While this study overall 
found that PCV/PPV had increased antibody protection over PPV, they primarily focused on the 
six-month endpoint for analysis rather than the four-week end point.  Six months after 
vaccination with PPV this study showed a significant increase in PCV/PPV compared to PPV 
whereas four weeks after vaccination there was not an increase in antibody response (Lesprit P 
& Group., 2007).   
The most recent study published in 2016 used PCV-13, making it most similar to our 
study (Sadlier C., 2016).  This study did examine the same serotypes that our study examined, 









study, this study separated the conjugate vaccine from the polysaccharide by four weeks 
instead of eight weeks, which may explain the slight alteration in antibody response in their 
results compared to our findings (Sadlier C., 2016).  This study also examined the antibody 
responses to pneumococcal polysaccharides both thirty and 196 days after vaccination with 
PPV (Sadlier C., 2016).  This was done to show whether the PPS-specific antibodies remained 
circulating six and a half months after vaccination.  Their primary end point for analysis of 
antibody production for HIV-infected adults vaccinated with PCV/PPV compared to PPV was 
196 days after PPV, in contrast to our study.  At this time point they found that PCV/PPV had a 
greater antibody response for ELISA and OPA for serotypes 3, 7F, and 19A.  However, thirty 
days after PPV vaccination there was no significant difference between PCV/PPV compared to 
PPV alone (Sadlier C., 2016). 
All five of these studies compared vaccination with PCV followed by PPV compared to 
PPV alone in HIV-infected adults, however, they did not have age-matched HIV-uninfected 
group to use as control groups for both the PCV/PPV and PPV alone.  However, the other 
studies did not restrict the age of their participants compared to our study, which focused on 
the aging HIV-infected population.  The process of aging correlates with increased inflammation 
which has been shown to decrease both humoral and adaptive immune responses.  Therefore, 
a lower median age in these other studies could have contributed to the differences in antibody 
responses between studies.  
 Immunological hypo-responsiveness to repeated vaccination has the potential to alter 
antibody responses (Poolman J, 2011).   The majority of our HIV+ participants were previously 
vaccinated with PPV in accordance with standard of care, whereas in contrast most if not all of 
our HIV‒ subjects were vaccine naive.  However, our lab and others have previously shown no 
differences in antibody responses between HIV+ participants who were vaccine naïve and those 
vaccinated with PPV ≥5 years prior, regardless of whether they received PPV or PCV/PPV (Iyer 









 There were no differences between post-vaccination anti-PPS 3 or 7F IgG concentrations 
between HIV- and HIV+ immunized with PCV/PPV or PPV.  The anti-PPS 19A IgG concentration, 
however, were significantly higher in HIV- compared to HIV+.  More importantly the bacterial 
killing specific to serotype 3 and 7F was significantly higher in HIV- compared to HIV+ who were 
vaccinated with only PPV.  This was however not the case for killing specific to serotype 19A 
vaccinated with PPV.  Immunization with PPV alone showed a significant increase in OPA titers 
in HIV+ patients compared to HIV-, however, the PCV/PPV groups did differ significantly. It 
seems immunization with PCV/PPV eradicated differences in opsonophagocytic antibody 
activity between HIV-and HIV+ groups in response to all serotypes as the opsonophagocytic 
activity was lower although not significantly, than the differences between HIV- compared to 
HIV+ in response to PPV alone.   
Pneumococcal polysaccharide specific ELISAs are designed to measure the amount of 
antibody present that are specific to that designated polysaccharide (Wernette CM, 2003).  
Unfortunately, this assay is not an exact measure of antibody response because polysaccharide 
in the vaccines are not pure.  The ELISA has been modified a number of times by incorporating 
blocking with cell wall polysaccharide (CWPS) and PPS serotype 22F that greatly reduce the 
amount of non-PPS specific binding, however, this is not perfect (Skovsted IC, 2007).  ELISAs are 
a quantitative assay, therefore they only measure the quantity of antibody or non-functional 
antibody response that have no direct effect on protecting the host from pneumococcus.  
Opsonophagocytic assays were designed to qualitatively measure the amount of bacterial 
killing by only measuring the bacteria that are opsonized by human antibody in combination 
with rabbit complement (Song JY, 2013).  While it is not feasible to directly measure protection 
achieved after vaccination, opsonophagocytic assays are a better correlate of protection 
compared to PPS-ELISAs because they measure the ability of the antibody produced to kill the 
bacteria.  
Increased age is shown to be associated with reduced pneumococcal vaccination responses, 









polysaccharide-specific IgM memory B cells are reduced in elderly individuals compared to 
younger volunteers’ post-PPV (Leggat D, 2013).  A strength of our study is the use of age-
matched uninfected controls for both PPV and PCV/PPV vaccination groups.  Overall there was 
no difference in IgG antibody response to vaccination with PCV/PPV versus PPV alone for the 
HIV+ individuals.  This trend was similar for HIV- individuals except in anti-PPS 19A IgG 
antibodies, where we found a significant increase when vaccinated with both PCV and PPV 
compared to only PPV.  Therefore, although HIV‒ participants had higher IgG levels and OPA 
titers compared to HIV+ volunteers, immunosenescence likely impacted humoral responses in 
all of our subjects. 
We determined that PCV/PPV may not demonstrate a clear immunological advantage 
compared to PPV alone in older HIV+ individuals, and antibody responses to PCV/PPV were 
reduced compared to HIV‒ PCV/PPV controls.  In addition, functional antibody killing specific to 
3, 7F, or 19A between PCV/PPV and only PPV showed no difference in bacterial killing ability in 
either the HIV-uninfected or HIV-infected population.  Development of more effective 
vaccination strategies in the aging HIV+ population may be very challenging as multiple 
comorbidities increase risk of pneumococcal infection.  Continued efforts aimed at improving 
vaccine protection in adults and understanding the immunological mechanisms responsible are 
critical.  A conjugate vaccine including other pneumococcal virulence factors like PspA or Ply 
may increase protection for those populations at high risk of pneumococcal infection.   
Previously, we have shown that after vaccination PCV/PPV or PPV alone there was 
inconsistent correlation between anti-PPS IgG antibody concentrations and OPA titers for 
pneumococcal serotypes 14 and 23F (Ohtola J, 2016).  This was consistent with other results 
after PPV vaccination showing that anti-PPS IgG specific to 14, 18C, and 23F produced after 
vaccination were inconsistently correlated to OPA titers (Park S, 2011).  Our results showed no 
correlation between anti-PPS specific to 3, 7F, and 19A compared to OPA titers for any group 









Five of the markers of immune activation that were tested IP-10, TNF-alpha, IL-6, sCD40L, 
and APRIL were significantly elevated in the HIV+ compared to the HIV- population.   This 
increase in inflammatory markers may be due to an elevated inflammatory state and viral 
replication that is present in the HIV infected adults compared to the HIV- adults.   
Interferon gamma-induced protein (IP-10), a pro-inflammatory chemokine, is secreted in 
response to IFN-gamma to induce chemo-attraction of lymphocytes by promoting cell 
adhesion. However, more importantly IP-10 has been previously implicated as a sensitive early 
marker of infection (Ng P., 2007).  IP-10 has previously been shown to be increased in HIV 
patients compared to HIV-uninfected patients, particularly those with long term controlled 
viremia (Noel N., 2014).  Levels of IP-10 are also increased in Hepatitis C infection, cystic fibrosis 
with acute pulmonary exacerbations, and other viral infections (Solomon G., 2013) (Grebely J., 
2013).  Additionally, higher levels of IP-10 in HIV infected patients correlate with an inadequate 
CD4 responses, implicating that increased IP-10 has been linked to poor immune responses 
(Stiksrud B., 2016).  Our results show that the HIV infected patients had increased levels of IP-
10 compared to their age matched HIV-uninfected adults.  This increase in serum concentration 
of IP-10 linked to inadequate CD4 responses could further explain why HIV-infected adults have 
poorer immune responses compared to the HIV-uninfected group. 
TNF-alpha primarily functions to regulate immune cells through the TNF cell signaling 
cascade.  The TNF cascade causes a range of cellular responses which include; cell death, 
survival, differentiation, proliferation, and migration.  Increased concentrations of TNF-alpha 
have been found in acute and chronic inflammatory states i.e. trauma, sepsis, and infections 
(Popa C., 2007).  Increased concentrations of TNF-alpha have been implicated in a number of 
other chronic inflammatory conditions including rheumatoid arthritis, ulcerative colitis, Crohn’s 
disease and even in the initiation and progression of cancer (Landskron G., 2014) (Sedger L., 
2014).  Previously, anti-TNF therapies have been used for treatment of inflammatory 
conditions, however, this therapy also increased the incidence of infections in these patients 









be beneficial in acute inflammation, however, chronic inflammation caused by increased TNF-
alpha is pathogenic to the host.  Serum concentrations of TNF-alpha are increased in HIV 
infection, however, individuals with AIDS have even higher concentrations when compared to 
those with controlled HIV infection (Aukrust P., 1994).  Our results show increased TNF 
concentrations in our HIV-infected population compared our HIV-uninfected cohort is 
consistent with previous results of increased inflammation caused by HIV-infection. 
An increased level of the pro-inflammatory cytokine IL-6 has previously been associated 
with poorer outcomes when diagnosed with community acquired pneumonia (Martínez, 2011).  
Higher level of IL-6 has also been shown to be associated with HIV replication, lower nadir CD4+ 
counts, and comorbid conditions (Lundgren, 2015).  Our results are similar to previous results 
showing that IL-6 is increased in HIV-infection.  IL-6 secretion has also been shown to induce 
the survival, population expansion, and maturation of B cells that produce a large amount of 
IgG (Hunter CA, 2015).  The increase in serum concentration of IL-6 that we observed in our 
HIV-infected population could be related to the increase in nonspecific and nonfunctional IgG 
antibodies that are secreted in HIV infection as a result of B cells dysregulation.  Increased IL-6 
could help to further explain results showing that although HIV-infected adults produce normal 
amounts of anti-PPS IgG in response to vaccination there is not significant bacterial killing post-
vaccination.  
CD40 is a costimulatory protein found on antigen presenting cells that is required for their 
activation.  The CD40 ligand is primarily expressed on T cells, and is currently thought to induce 
B cell differentiation, class switching, and antibody secretion.  However, it has also been shown 
that B cells can produce this ligand on their surface following activation and can even secrete a 
soluble form of this ligand (Wykes, 2003).  In fact, CD40L expressed on B cells is structurally 
identical with that expressed by activated T cells (Grammer AC, 1995).  B cells lines expressing 
CD40 ligand can induce IgG production from a resting B cell in a CD40 dependent manner 
(Grammer AC, 1995).  During HIV infection alterations in IL-12 expression has been shown to 









may play an immunosuppressive role during HIV-infection by suppressing regulatory T cell 
expansion (Jenabian M., 2014).  Previously our lab has shown that HIV-infected adults have 
increased expression of CD40 on their B cells that specifically respond to PPS compared to HIV-
uninfected individuals after vaccination, however, prior to vaccination there was not a 
significant difference in either PPS selected or unselected B cells in HIV-infected compared to 
HI-uninfected (Iyer A., 2016).   Our current results show that HIV-infected groups had increased 
concentrations of sCD40L compared to our HIV-uninfected group prior to vaccination.   It can be 
postulated that this increased expression sCD40L in our HIV-infected population compared to 
our HIV-uninfected may be due to dysregulation of sCD40L expression suppressing regulatory T 
cell expansion. 
APRIL, which binds to TACI and BCMA, is an important ligand in B cell development that has 
been implemented in long term plasma cell survival.  Previously, our lab has shown that soluble 
TACI expression was lower in HIV-infected individuals (Iyer A., 2016).  TACI has been linked to 
antibody production during a T cell independent type II response; in fact TACI deficient mice 
showed significant defects in producing T cell independent type II specific IgG and IgM (G. von 
Bulow, 2001).  APRIL mediates signals promoting class-switching and TI-II responses through 
interactions with TACI.  Interestingly higher serum levels of APRIL have been associated with 
various inflammatory disease including; anti-glomular basement membrane disease, pediatric 
lupus, and juvenile arthritis (Ezzat M., 2016) (Marsushita T., 2007).  Serum concentrations of 
APRIL have also been postulated to be a marker of predicting disease activity and severity in 
patients with systemic lupus erythematosus (Boghdadi G., 2014).  Our HIV-infected participants 
had increased levels of APRIL compared to the HIV-uninfected group.  The increase in APRIL 
expression in our HIV-infected volunteers compared to our HIV-uninfected is likely a cause of 
increased inflammatory environment caused by HIV infection. 
We were not able to define one marker of immune activation tested that was associated 
with increased or decreased functional antibody response across all groups (data not shown).  









that combination of several inflammatory markers correlate with functional antibody activity.  
There were three instances where there was a significant correlation seen between OPA titers 
and inflammatory markers (IL-10, IL-8, IP-10, IL-6, TNF-alpha,  IL-1RA, and sCD40L), however, 
these results were inconsistent and were only seen in consistent across either patient group or 
vaccine groups.  Therefore, we can generalize that we did not see an overall correlation 






























Chapter 6: Conclusions and Summary 
 We analyzed the immune response to PPS 3, 7F, and 19A in aging HIV+ and HIV- adults.  
We did not find an overall benefit in immunizing with PCV/PPV compared to receiving PPV.   
There was an increase in functional antibody response in the HIV- groups compared to the HIV+ 
groups for pneumococcal serotypes 3 and 7F when vaccinated with PPV alone, however, this 
was not true for serotype 19A or any group immunized with both PCV and PPV.  We have also 
shown that IP-10, TNF-alpha, IL-6, sCD40L, and APRIL serum concentrations are elevated in HIV-
infected adults compared to HIV-uninfected adults associated with increased inflammatory 
state and B cell dysregulation associated with HIV infection.  We found no association between 
anti-PPS IgG antibody concentrations with opsonophagocytic activity regardless of vaccination 
strategy.  There was also no single marker of immune activation that correlated with functional 

























Table 1. Study volunteer groups distribution 
 
 N= Age Nadir CD4 Current CC4 Viral load 




N/A N/A N/A 









Group 3:  HIV- age 50-65 
receiving PCV followed by PPV 
15 57 
(50-65) 
N/A N/A N/A 
Group 4:  HIV+ age 50-65 















Table 2. Vaccine serotype coverage. 
 
PCV-7 Conjugate PCV-13 Conjugate Vaccine PPV-23 Pneumovax 
4, 6B, 9V, 14, 18C, 19F and 
23F 
1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 
18C, 19A, 19F and 23F 
1, 2, 3, 4, 5, 6b, 7F, 8, 9N, 9V, 
10A, 11A, 12F, 14, 15B, 17F, 





















Figure 1. Pneumococcal antibody concentrations of serotype 3 (a), 7F (b), and 19A (c) between 





A. Anti PPS 3 ELISA Group 1 vs Group 2 
B. Anti PPS 7F ELISA Group 1 vs Group 2 
C. Anti PPS 19A ELISA Group 1 vs Group 2 
Anti-PPS ELISAs were determined in aging HIV+ and HIV uninfected adults. Gray spotted bars= 














Figure 2: Pneumococcal antibody concentrations of serotype 3 (a), 7F (b), and 19A (c) between 






A. Anti PPS 3 ELISA Group 3 vs Group 4 
B. Anti PPS 7F ELISA Group 3 vs Group 4 
C. Anti PPS 19A ELISA Group 3 vs Group 4 
Anti-PPS ELISAs were determined in aging HIV+ and HIV uninfected adults. Gray spotted bars= 











Figure 3: Pneumococcal antibody concentrations of serotype 3 (a), 7F (b), and 19A (c) between 
HIV-infected individuals vaccinated with PCV/PPV compared with PPV alone 





A. Anti PPS 3 ELISA Group 2 vs Group 4 
B. Anti PPS 7F ELISA Group 2 vs Group 4 
C. Anti PPS 19A ELISA Group 2 vs Group 4 
Anti-PPS ELISAs were determined in aging HIV+ and HIV uninfected adults. Gray spotted bars= 









Figure 4: Pneumococcal antibody concentrations of serotype 3 (a), 7F (b), and 19A (c) between 





A. Anti PPS 3 ELISA Group 1 vs Group 3 
B. Anti PPS 7F ELISA Group 1 vs Group 3 
C. Anti PPS 19A ELISA Group 1 vs Group 3 
Anti-PPS ELISAs were determined in aging HIV+ and HIV uninfected adults. Gray spotted bars= 











Figure 5: Pneumococcal antibody mediated killing of serotype 3 (a), 7F (b), and 19A (c) between 









A.PPV only OPA Pn3 Group 2 vs Group 1 
B.PPV only OPA Pn7F Group 2 vs Group 1 









Serum opsonophagocytic assay (OPA) titers were determined in aging HIV+ and HIV 
uninfected adults. White bars= baseline, Shaded bars = 1 month post PPV, *, p < 0.05; **, p < 










































































Figure 6: Pneumococcal antibody mediated killing of serotype 3 (a), 7F (b), and 19A (c) between 
HIV-infected and HIV-uninfected who were vaccinated with PCV/PPV 
   
 
 
A.PCV/PPV OPA Pn3 Group 4 vs Group 3 
B.PCV/PPV OPA Pn7F Group 4 vs Group 3 












Serum opsonophagocytic assay (OPA) titers were determined in aging HIV+ and HIV 
uninfected adults. White bars= baseline, Shaded bars = 1 month post PPV, *, p < 0.05; **, p < 









































Figure 7: Pneumococcal antibody mediated killing of serotype 3 (a), 7F (b), and 19A (c) between 






A.HIV+ only OPA Pn3 Group 2 vs. Group 4 
B.HIV+ only OPA Pn7F Group 2 vs Group 4 















Serum opsonophagocytic assay (OPA) titers were determined in aging HIV+ and HIV 
uninfected adults. White bars= baseline, Shaded bars = 1 month post PPV, *, p < 0.05; **, p < 









Figure 8: Pneumococcal antibody mediated killing of serotype 3 (a), 7F (b), and 19A (c) between 







A.HIV- only OPA Pn3 Group 1 vs. Group 3 
B.HIV- only OPA Pn7F Group 1 vs Group 3 











Serum opsonophagocytic assay (OPA) titers were determined in aging HIV+ and HIV 
uninfected adults. White bars= baseline, Shaded bars = 1 month post PPV, *, p < 0.05; **, p < 
0.005; and ***, p < 0.0001.  

















A. APRIL, B. BAFF, C. IL-10, D. sCD40L, E. IL-1RA, F. IL-1B, 





Markers of immune activation between HIV-infected and HIV-uninfected individuals; *, 
p < 0.05; **, p < 0.005; and ***, p < 0.0001. 
 
























Correlations between pneumococcal serotype specific 3 post-PPV OPA titers and markers of 
immune activation in aging HIV-infected adults A. APRIL, B. BAFF, C. IL-10, D. sCD40L, E. 
IL-1RA, F. IL-1B, G. IL-6, H. IL-8, I. IP-10, J. TNF-alpha 
Group 
2 




IL-1b IL-6 IL-8 IP-10 TNF-a 
R =  -0.116 0.174 0.261 -0.046 0.199 0.3951 0.0926 0.176 0.095 0.0212 
P = 0.617 0.450 0.254 0.847 0.387 0.1449 0.715 0.443 0.758 0.9274 
 
 
Figure 11 Pn 3 Group 1 OPA vs. Inflammatory Markers HIV- PPV (bolded=significant) 
PPV Pn3 OPA and April (HIV)
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Correlations between pneumococcal serotype specific 3 post-PPV OPA titers and markers of 
immune activation in aging HIV-uninfected adults A. APRIL, B. BAFF, C. IL-10, D. sCD40L, 
E. IL-1RA, F. IL-1B, G. IL-6, H. IL-8, I. IP-10, J. TNF-alpha 
Group 
1 
APRIL BAFF IL-10 sCD40
L 
IL-1Ra IL-1b IL-6 IL-8 IP-10 TNF-a 
R =  -0.2918 -0.085 0.609 0.571 0.134 0.167 Only 2 0.125 -0.23 0.7112 
P = 0.4133 0.815 0.062 0.180 0.713 0.693 points 0.748 0.521 0.0211 
 
Figure 12 Pn 3 Group 4 OPA vs. Inflammatory Markers HIV+ PCV/PPV (bolded=significant) 
PPV Pn3 OPA and April (HIV-)
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PPV Pn3 OPA and IL-1B (HIV-)

















PPV Pn3 OPA and IL-6 (HIV-)














PPV Pn3 OPA and IL-8 (HIV-)















PPV Pn3 OPA and IP-10 (HIV-)













PPV Pn3 OPA and TNF-alpha (HIV-)

































Correlations between pneumococcal serotype specific 3 post-PCV/PPV OPA titers and markers 
of immune activation in aging HIV-infected adults. A. APRIL, B. BAFF, C. IL-10, D. sCD40L, 
E. IL-1RA, F. IL-1B, G. IL-6, H. IL-8, I. IP-10, J. TNF-alpha 
Group 
4 
APRIL BAFF IL-10 sCD40
L 
IL-1Ra IL-1b IL-6 IL-8 IP-10 TNF-
a 
R =  -0.1357 -0.061 -0.117 -0.556 -0.393 -0.25 -0.14 -0.51 -0.55 0.833 
P = .5797 0.805 0.631 0.016 0.096 0.368 0.64 0.038 0.018 0.001 
Figure 13 Pn 3 Group 3 OPA vs. Inflammatory Markers HIV- PCV/PPV (bolded=significant) 
Pn3 OPA and April (HIV)
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Correlations between pneumococcal serotype specific 3 post-PCV/PPV OPA titers and markers 
of immune activation in aging HIV-uninfected adults A. APRIL, B. BAFF, C. IL-10, D. 
sCD40L, E. IL-1RA, F. IL-1B, G. IL-6, H. IL-8, I. IP-10, J. TNF-alpha 
Group 
3 
APRIL BAFF IL-10 sCD40L IL-
1Ra 
IL-1b IL-6 IL-8 IP-10 TNF-a 
R =  0.224 -0.37 0.339 -0.110 0.013 -0.166 0.242 -0.116 0.013 0.140 
P = 0.4226 0.169 0.216 0.795 0.965 0.501 0.499 0.679 0.964 0.566 
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Figure 14 Pn 7F Group 1 OPA vs. Inflammatory Markers HIV+ PPV (bolded=significant) 
 
Correlations between pneumococcal serotype specific 7F post-PPV OPA titers and markers of 
immune activation in aging HIV-infected adults A. APRIL, B. BAFF, C. IL-10, D. sCD40L, E. 
IL-1RA, F. IL-1B, G. IL-6, H. IL-8, I. IP-10, J. TNF-alpha 
Group 
1 
APRIL BAFF IL-10 sCD40L IL-
1Ra 
IL-1b IL-6 IL-8 IP-10 TNF-a 
R =  -0.046 0.232 0.187 0.114 0.151 -0.089 0.0698 0.495 0.145 0.0937 
P = 0.840 0.339 0.443 0.653 0.538 0.715 0.776 0.031 0.552 0.7027 
Figure 15 Pn 7F Group 1 OPA vs. Inflammatory Markers HIV- PPV 
PPV Pn7F OPA and April (HIV)
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Correlations between pneumococcal serotype specific 7F post-PPV OPA titers and markers of 
immune activation in aging HIV-uninfected adults A. APRIL, B. BAFF, C. IL-10, D. sCD40L, 
E. IL-1RA, F. IL-1B, G. IL-6, H. IL-8, I. IP-10, J. TNF-alpha 
Group 
2 
APRIL BAFF IL-10 sCD40L IL-
1Ra 
IL-1b IL-6 IL-8 IP-10 TNF-a 
R =  -0.368 -0.260 -0.163 -0.573 0.145 -0.067 0.285 -0.046 0.191 -0.386 
P = 0.177 0.349 0.561 0.108 0.606 0.814 0.304 0.869 0.494 0.155 
Figure 16 Pn 7F Group 4 OPA vs. Inflammatory Markers HIV+ PCV/PPV 
PPV Pn7F OPA and April (HIV-)
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Correlations between pneumococcal serotype specific 7F post-PCV/PPV OPA titers and markers 
of immune activation in aging HIV-infected adults A. APRIL, B. BAFF, C. IL-10, D. sCD40L, 
E. IL-1RA, F. IL-1B, G. IL-6, H. IL-8, I. IP-10, J. TNF-alpha 
Group 
4 
APRIL BAFF IL-10 sCD40
L 
IL-1Ra IL-1b IL-6 IL-8 IP-10 TNF-a 
R =  -0.200 -0.436 0.276 -0.183 -0.045 0.0386 -0.525 0.025 0.055 0.242 
P = 0.384 0.048 0.225 0.427 0.846 0.8679 0.014 0.914 0.812 0.291 
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Figure 17 Pn 7F Group 3 OPA vs. Inflammatory Markers HIV- PCV/PPV 
 
Correlations between pneumococcal serotype specific 7F post-PCV/PPV OPA titers and markers 
of immune activation in aging HIV-infected adults. A. APRIL, B. BAFF, C. IL-10, D. sCD40L, 
E. IL-1RA, F. IL-1B, G. IL-6, H. IL-8, I. IP-10, J. TNF-alpha 
Group 
3 
APRIL BAFF IL-10 sCD40L IL-
1Ra 
IL-1b IL-6 IL-8 IP-10 TNF-a 
R =  -0.498 0.013 0.098 0.148 0.123 0.123 -0.309 -0.188 -0.084 0.304 
P = 0.144 0.973 0.785 0.783 0.733 0.733 0.387 0.607 0.811 0.387 
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Figure 18 Pn 19A Group 2 OPA vs. Inflammatory Markers HIV+ PPV 
 
Correlations between pneumococcal serotype specific 19A post-PPV OPA titers and markers of 
immune activation in aging HIV-infected adults A. APRIL, B. BAFF, C. IL-10, D. sCD40L, E. 
IL-1RA, F. IL-1B, G. IL-6, H. IL-8, I. IP-10, J. TNF-alpha 
Group 
2 
APRIL BAFF IL-10 sCD40
L 
IL-1Ra IL-1b IL-6 IL-8 IP-10 TNF-
a 
R =  -0.039 0.272 -0.485 -0.134 -0.074 0.258 -0.363 -0.155 -0.528 0.31 
P = 0.867 0.234 0.026 0.572 0.751 0.353 0.139 0.503 0.0635 0.27 
Figure 19 Pn 19A Group 1 OPA vs. Inflammatory Markers HIV- PPV 
PPV Pn19A OPA and April (HIV)
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Correlations between pneumococcal serotype specific 19A post-PPV OPA titers and markers of 
immune activation in aging HIV-uninfected adults A. APRIL, B. BAFF, C. IL-10, D. sCD40L, 
E. IL-1RA, F. IL-1B, G. IL-6, H. IL-8, I. IP-10, J. TNF-alpha 
Group 
1 
APRIL BAFF IL-10 sCD40L IL-1Ra IL-1b IL-6 IL-8 IP-10 TNF-a 
R =  0.424 0.316 0.0675 0.816 0.249 0.119 0.174 -0.45 0.103 0.300 
P = 0.918 0.368 0.865 0.006 0.492 0.792 0.632 0.230 0.785 0.436 
 
Figure 20 Pn 19A Group 4 OPA vs. Inflammatory Markers HIV+ PCV/PPV 
PPV Pn19A OPA and April (HIV-)
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Correlations between pneumococcal serotype specific 19A post-PCV/PPV OPA titers and 
markers of immune activation in aging HIV-infected adults A. APRIL, B. BAFF, C. IL-10, D. 
sCD40L, E. IL-1RA, F. IL-1B, G. IL-6, H. IL-8, I. IP-10, J. TNF-alpha 
Group 
4 
APRIL BAFF IL-10 sCD40L IL-1Ra IL-1b IL-6 IL-8 IP-10 TNF-a 
R =  -0.089 -0.248 0.107 0.203 -0.189 -0.349 0.385 0.083 0.459 -0.160 
P = 0.716 0.305 0.663 0.418 0.453 0.242 0.194 0.751 0.055 0.526 
 
 
Figure 21 Pn 19A Group 3 OPA vs. Inflammatory Markers HIV- PCV/PPV 
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Correlations between pneumococcal serotype specific 19A post-PCV/PPV OPA titers and 
markers of immune activation in aging HIV-uninfected adults A. APRIL, B. BAFF, C. IL-10, D. 
sCD40L, E. IL-1RA, F. IL-1B, G. IL-6, H. IL-8, I. IP-10, J. TNF-alpha 
Group 
3 
APRIL BAFF IL-10 sCD40L IL-1Ra IL-1b IL-6 IL-8 IP-10 TNF-a 
R =  0.396 0.485 0.029 0.051 0.204 0.055 -0.012 0.439 0.169 0.515 
P = 0.144 0.067 0.919 0.912 0.467 0.892 0.973 0.101 0.563 0.133 
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